{"id":11910,"date":"2025-06-17T10:34:44","date_gmt":"2025-06-17T08:34:44","guid":{"rendered":"https:\/\/valintermed.com\/?p=11910"},"modified":"2025-06-17T10:34:44","modified_gmt":"2025-06-17T08:34:44","slug":"reshetchataya-distrofiya-rogovitsy-tip-2","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/","title":{"rendered":"Lattice corneal dystrophy type 2"},"content":{"rendered":"<div class=\"fpm_start\"><\/div>\n<p>Ribbon-like dystrophy type 2 is a hereditary disease characterized by progressive damage to the corneal stroma with the formation of specific protein deposits. The pathology belongs to the group of primary corneal dystrophies and manifests itself in the form of linear or ribbon-like optically dense formations located mainly in the anterior layers of the stroma. The clinical picture includes a gradual decrease in visual acuity, photophobia and discomfort when wearing contact lenses. A feature of this type of dystrophy is a more severe course compared to type 1, which is due to the earlier onset and rapid progression of the pathological process.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-flat ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Content<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\" >History of the disease and interesting historical facts<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F_%D1%81%D1%82%D0%B0%D1%82%D0%B8%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Epidemiology (statistics of disease occurrence)<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E_%D0%B2%D0%BE%D0%B2%D0%BB%D0%B5%D1%87%D1%91%D0%BD%D0%BD%D1%8B%D0%B5_%D0%B3%D0%B5%D0%BD%D1%8B_%D0%B8_%D0%BC%D1%83%D1%82%D0%B0%D1%86%D0%B8%D0%B8\" >Genetic predisposition to the disease (involved genes and mutations)<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Risk factors for the development of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Diagnosis of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\" >Treatment<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >List of drugs used to treat this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%BA%D0%BE%D0%BD%D1%82%D1%80%D0%BE%D0%BB%D1%8C%D0%BD%D1%8B%D0%B5_%D1%8D%D1%82%D0%B0%D0%BF%D1%8B_%D0%BF%D1%80%D0%BE%D0%B3%D0%BD%D0%BE%D0%B7_%D0%BE%D1%81%D0%BB%D0%BE%D0%B6%D0%BD%D0%B5%D0%BD%D0%B8%D1%8F\" >Disease monitoring (control stages, prognosis, complications)<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%BA%D0%B0%D0%BA_%D0%BF%D1%80%D0%BE%D1%82%D0%B5%D0%BA%D0%B0%D0%B5%D1%82_%D0%B2_%D1%80%D0%B0%D0%B7%D0%BD%D1%8B%D1%85_%D0%B2%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D1%85_%D0%B3%D1%80%D1%83%D0%BF%D0%BF%D0%B0%D1%85\" >Age-related features of the disease (how it progresses in different age groups)<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\" >Questions and Answers<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/reshetchataya-distrofiya-rogovitsy-tip-2\/#%D0%A1%D0%BE%D0%B2%D0%B5%D1%82%D1%8B_%D0%BE%D1%82_%D0%B4%D0%BE%D0%BA%D1%82%D0%BE%D1%80%D0%B0_%D0%9E%D0%BB%D0%B5%D0%B3%D0%B0_%D0%9A%D0%BE%D1%80%D0%B6%D0%B8%D0%BA%D0%BE%D0%B2%D0%B0\" >Advice from Dr. Oleg Korzhikov<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\"><\/span>History of the disease and interesting historical facts<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The first descriptions of lattice corneal dystrophy appeared in the mid-20th century, when ophthalmologists began to systematize various forms of hereditary corneal dystrophies. In 1967, Bjornstad and Tonnesen described the clinical picture of the disease in detail, noting the characteristic ribbon-like shape of the deposits. Interestingly, it was during the study of this pathology that modern methods of genetic diagnostics in ophthalmology were first used. \u201cThis disease became the starting point for understanding the molecular mechanisms of the development of hereditary corneal dystrophies,\u201d notes a study in the Journal of Medical Genetics, 1995.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F_%D1%81%D1%82%D0%B0%D1%82%D0%B8%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Epidemiology (statistics of disease occurrence)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Lattice corneal dystrophy type 2 occurs with a frequency of approximately 1 case per 500,000 population. The disease has a universal distribution, but some studies indicate a higher frequency of detection in Scandinavian populations. According to statistics:<\/p>\n<ul>\n<li>The average age of manifestation is 20-30 years.<\/li>\n<li>Men and women are affected with equal frequency<\/li>\n<li>In approximately 85% cases, the disease manifests itself before age 40<\/li>\n<li>The penetrance of the mutation reaches 95%<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E_%D0%B2%D0%BE%D0%B2%D0%BB%D0%B5%D1%87%D1%91%D0%BD%D0%BD%D1%8B%D0%B5_%D0%B3%D0%B5%D0%BD%D1%8B_%D0%B8_%D0%BC%D1%83%D1%82%D0%B0%D1%86%D0%B8%D0%B8\"><\/span>Genetic predisposition to the disease (involved genes and mutations)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The disease is inherited in an autosomal dominant manner and is associated with mutations in the TGFBI (transforming growth factor beta-induced) gene, located on chromosome 5q31. The most common mutation is R124H, which results in the replacement of arginine with histidine at position 124. The mechanism of pathogenesis is associated with the accumulation of mutated keratoepithelin protein in the corneal stroma. Studies show that &quot;the mutated protein forms aggregates that disrupt the normal structure of collagen fibrils,&quot; as stated in the American Journal of Ophthalmology, 2001.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Risk factors for the development of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Although the main factor in development is genetic predisposition, there are additional factors that contribute to the acceleration of the disease progression:<\/p>\n<ul>\n<li>Long-term exposure to ultraviolet radiation<\/li>\n<li>Corneal injuries of various etiologies<\/li>\n<li>Chronic inflammatory processes of the ocular surface<\/li>\n<li>Disorders of amino acid metabolism<\/li>\n<li>Effects of toxic substances on the ocular surface<\/li>\n<\/ul>\n<p>The combined effects of several factors simultaneously are especially dangerous.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Diagnosis of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The main symptoms include gradual loss of vision, photophobia and blurred vision. The diagnostic algorithm includes the following methods:<\/p>\n<ul>\n<li>Slit lamp biomicroscopy reveals characteristic band-like deposits<\/li>\n<li>Confocal microscopy - assessment of lesion depth<\/li>\n<li>Keratotopography - determination of the degree of corneal irregularity<\/li>\n<li>Genetic testing - confirmation of R124H mutation<\/li>\n<\/ul>\n<p>Differential diagnosis is carried out with other forms of hereditary corneal dystrophies, as well as with secondary corneal opacities.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\"><\/span>Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>General therapy is aimed at slowing the progression of the disease and correcting refractive disorders. Pharmacological treatment includes the use of drugs that stabilize corneal metabolism. In case of significant vision loss, surgical treatment is indicated:<\/p><script data-noptimize=\"\" data-wpfc-render=\"false\">\nfpm_start( \"true\" );\n<\/script>\n\n<ul>\n<li>Photorefractive keratectomy (PRK) - in early stages<\/li>\n<li>Corneal transplant (keratoplasty) - for severe changes<\/li>\n<li>Laser therapy - to remove superficial deposits<\/li>\n<\/ul>\n<p>Alternative treatments include collagen crosslinking.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>List of drugs used to treat this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Corticosteroid drops (Dexamethasone 0.1%) - to control inflammation<\/li>\n<li>Artificial tears (Hypromellose 0.3%) - for moisturizing<\/li>\n<li>Antioxidants of local action (Taurine 4%) - to protect the epithelium<\/li>\n<li>Anti-inflammatory drugs (Diclofenac 0.1%) - during exacerbation<\/li>\n<li>Antimetabolites (Mitomycin-C) - during PRK<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%BA%D0%BE%D0%BD%D1%82%D1%80%D0%BE%D0%BB%D1%8C%D0%BD%D1%8B%D0%B5_%D1%8D%D1%82%D0%B0%D0%BF%D1%8B_%D0%BF%D1%80%D0%BE%D0%B3%D0%BD%D0%BE%D0%B7_%D0%BE%D1%81%D0%BB%D0%BE%D0%B6%D0%BD%D0%B5%D0%BD%D0%B8%D1%8F\"><\/span>Disease monitoring (control stages, prognosis, complications)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Regular monitoring includes annual examinations with biomicroscopy and keratotopography. The prognosis with timely treatment is relatively favorable, but complications are possible:<\/p>\n<ul>\n<li>Development of postoperative astigmatism<\/li>\n<li>Graft rejection in keratoplasty<\/li>\n<li>Recurrence of deposits in donor cornea<\/li>\n<li>The occurrence of secondary glaucoma<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%BA%D0%B0%D0%BA_%D0%BF%D1%80%D0%BE%D1%82%D0%B5%D0%BA%D0%B0%D0%B5%D1%82_%D0%B2_%D1%80%D0%B0%D0%B7%D0%BD%D1%8B%D1%85_%D0%B2%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D1%85_%D0%B3%D1%80%D1%83%D0%BF%D0%BF%D0%B0%D1%85\"><\/span>Age-related features of the disease (how it progresses in different age groups)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At a young age, the disease is more aggressive, with rapid progression of changes. In older patients, the pathological process develops more slowly, which may be associated with a general slowdown in metabolic processes. However, elderly patients have a higher risk of complications after surgical treatment.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\"><\/span>Questions and Answers<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>How often should you undergo examination for this disease?<\/strong> An annual examination is recommended, and if progression occurs, every 6 months.<\/li>\n<li><strong>Is it possible to prevent the development of the disease?<\/strong> It is impossible to prevent it completely, but its progression can be slowed down.<\/li>\n<li><strong>How does pregnancy affect the course of the disease?<\/strong> May temporarily worsen the condition due to hormonal changes.<\/li>\n<li><strong>Is the disease transmitted to offspring?<\/strong> Yes, the risk of transmission is 50%.<\/li>\n<li><strong>Does nutrition affect the course of the disease?<\/strong> An antioxidant diet may slow progression.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BE%D0%B2%D0%B5%D1%82%D1%8B_%D0%BE%D1%82_%D0%B4%D0%BE%D0%BA%D1%82%D0%BE%D1%80%D0%B0_%D0%9E%D0%BB%D0%B5%D0%B3%D0%B0_%D0%9A%D0%BE%D1%80%D0%B6%D0%B8%D0%BA%D0%BE%D0%B2%D0%B0\"><\/span>Advice from Dr. Oleg Korzhikov<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Patients often ask: &quot;Can I use contact lenses with this disease?&quot; Answer: in the early stages, it is possible to wear special rigid gas-permeable lenses, but under strict supervision of a doctor. &quot;How can I protect my eyes from deterioration?&quot; many people ask. I recommend using high-quality sunglasses with a UV filter of categories 3-4. An important question: &quot;When should I plan an operation?&quot; A decision must be made when visual acuity decreases below 0.5 or severe discomfort appears.<\/p>\n<div class=\"fpm_end\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Ribbon-like dystrophy type 2 is a hereditary disease characterized by progressive damage to the corneal stroma with the formation of<\/p>","protected":false},"author":1,"featured_media":20449,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[298],"tags":[],"class_list":["post-11910","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medlibrary"],"_links":{"self":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/comments?post=11910"}],"version-history":[{"count":1,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11910\/revisions"}],"predecessor-version":[{"id":15288,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11910\/revisions\/15288"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media\/20449"}],"wp:attachment":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media?parent=11910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/categories?post=11910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/tags?post=11910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}